Go Pro
NASDAQ:COCH

Envoy Medical Q2 2026 Earnings Report

Envoy Medical logo
$0.76 +0.04 (+5.06%)
Closing price 07/16/2026 04:00 PM Eastern
Extended Trading
$0.78 +0.02 (+2.62%)
As of 07:48 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Envoy Medical EPS Results

Actual EPS
N/A
Consensus EPS
-$0.08
Beat/Miss
N/A
One Year Ago EPS
N/A

Envoy Medical Revenue Results

Actual Revenue
N/A
Expected Revenue
$0.10 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Envoy Medical Announcement Details

Quarter
Q2 2026
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Envoy Medical Earnings Headlines

Envoy Medical (NASDAQ:COCH) Trading 9.4% Higher - Should You Buy?
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in 50 years - and it has nothing to do with a single stock. According to multiple Wall Street banks, a coming crisis could keep your portfolio in the red for 10 years or longer. Keith Kaplan, CEO of TradeSmith, is sharing what you can do to protect your wealth before it hits.tc pixel
Envoy Medical Inc - Ordinary Shares - Class A
See More Envoy Medical Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Envoy Medical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Envoy Medical and other key companies, straight to your email.

About Envoy Medical

Envoy Medical (NASDAQ:COCH) (NASDAQ:COCH) is a medical device company focused on non-invasive neuromodulation therapies for dysphagia, a swallowing disorder that affects patients following neurological events or due to degenerative conditions. The company’s lead technology delivers targeted electrical stimulation designed to strengthen the muscles and neural pathways involved in the swallowing process.

Envoy Medical’s flagship therapy has received regulatory clearance from the U.S. Food and Drug Administration and is being introduced through rehabilitation centers, speech-language pathology clinics and acute care hospitals. The company works closely with healthcare providers to integrate its device into patient care pathways, supporting therapy both in clinical environments and at home.

Headquartered in the Minneapolis–Saint Paul metropolitan area, Envoy Medical currently serves the U.S. market and is evaluating opportunities for expansion into select international regions. Its leadership team combines expertise in medical device development, rehabilitation sciences and commercial operations, backed by private financing aimed at advancing innovative therapies for neurological and musculoskeletal disorders.

View Envoy Medical Profile